Home
Hope • Science • Life
We bring
hope to life
People facing life-threatening diseases need the possibility of tomorrow. We bring them hope through life-saving medicines, today.
We bring
hope to life
People facing life-threatening diseases need the possibility of tomorrow. We bring them hope through life-saving medicines, today.
Resources & Patient Stories
We create innovative, life-saving treatments and bring hope to those facing life-altering conditions with no approved disease-modifying therapies or cures.
Resources & Patient Stories
We create innovative, life-saving treatments and bring hope to those facing life-altering conditions with no approved disease-modifying therapies or cures.
21st Annual Needham Virtual Healthcare Conference
The 21st Annual Needham Virtual Healthcare Conference took place on April 11-14, 2022 and featured fireside chats and presentations from leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology, and Diagnostics sectors. Watch as NRx CEO Robert Besthof, M.I.M. gave a corporate presentation.

Right to Try
Aviptadil Right to Try – for US-licensed physicians who wish to obtain Aviptadil under Right to Try laws for Critical COVID-19 patients with no therapeutic alternative.
We go after the most critical medical conditions and unmet needs.
We audaciously work to research, develop, and scale solutions to help people that desperately need them.
We accomplish our mission by directing deep scientific and clinical expertise towards innovative clinical development protocol, while simultaneously investing in scalability and stability to ensure our medicines are easily accessible to people around the world.
Discovery Pipeline
Highlights
NRX-101 An investigational, rapid-onset and sustained treatment for Bipolar Depression in patients with Acute Suicidal Ideation and Behavior.
ZYESAMI® has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA)for the treatment of Critical COVID-19 with respiratory failure, and is now in clinical trials.
ZYESAMI® (Aviptadil) is an investigational medicine for the treatment of Acute Respiratory Failure in patients with Critical COVID-19, and for the prevention of respiratory failure in patients with Severe COVID-19.
ZYESAMI® is a proprietary, shelf-stable formulation of Aviptadil, a synthetic form of human Vasoactive Intestinal Peptide (VIP). VIP is an endogenous substance produced by the body that, among other functions, helps protect cells against inflammatory conditions.